Skip to main content

Table 2 Change in HbA1c at 6 months post-initiation of second-line treatment, stratified by baseline HbA1c category

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Baseline HbA1c

N

Mean change at 6 months (standard error)

N (%) with fall ≥ 0.5% at 6 months

%

mmol/mol

%

mmol/mol

<7.5

< 58

811

0.02 (0.04)

0.2 (0.4)

277 (34.2)

7.5 to <9.0

58 to <75

2751

−0.71 (0.02)

−7.8 (0.2)

1855 (67.4)

9.0 to <10.5

75 to <91

1325

−1.47 (0.04)

−16.1 (0.4)

1099 (82.9)

10.5 to <12.0

91 to <108

715

−2.48 (0.06)

−27.1 (0.7)

641 (89.7)

≥12.0

≥108

440

−4.40 (0.12)

−48.1 (1.3)

405 (92.1)

Overall

 

6042

−1.26 (0.02)

−13.8 (0.2)

4277 (70.8)

  1. Data from patients who had available HbA1c measurements at 6 months and at baseline, and who were on-treatment at 6 months (i.e. had not switched, intensified or discontinued second-line treatment since the previous time point)